Method of detecting bladder cancer
Provided is a sensitizing detection agent of an oral or intravenous administration type which enables the detection of bladder cancer with a higher sensitivity without causing pain to the patient. A sensitizing detection agent for bladder cancer comprising 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is orally or intravenously administered, and a video camera system is inserted via the urethra and a blue light at 380-440 nm is irradiated to observe the red fluorescent part. Further, VLD-M1 is inserted and a blue light at 405 nm is irradiated to observe fluorescence intensity (relative intensity) of the red light part. For oral administration, 20 mg/kg (maximum of 1 g) of ALA is dissolved in 50 mL of a 5% glucose solution prior to the administration.
1. A method of detecting bladder cancer comprising the sequential steps of:
(a) orally administering to a mammal a bladder cancer detecting sensitizer which comprises 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these, wherein the oral administration of the sensitizer to the mammal delivers 10 to 50 mg ALA per kilo body weight in ALA hydrochloride equivalent or a molar equivalent of the derivative or the salt thereof;
(b) irradiating the mammalian bladder with an excitation light of 380-440 nm; and
(c) detecting fluorescence intensity at red light part of the bladder,
wherein steps (b) and (c) are performed between 2 hours and less than 5 hours after step (a).
2. The detection method according to claim 1 , wherein the 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is 5-aminolevulinic acid or a salt thereof.
3. The detection method according to claim 1 , wherein the bladder cancer is at a disease stage of pTis (intraepithelial cancer), pTa (without invasion), pT1 (with invasion to submucosal connective tissue), pT2 (with muscle invasion), or pT3 (with invasion to pericystic adipose tissue).
4. The detection method according to claim 3 , wherein the 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is 5-aminolevulinic acid or a salt thereof.
5. A method of detecting bladder cancer comprising the sequential steps of:
(a) intravenously injecting to a mammal a bladder cancer detecting sensitizer which comprises 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these, wherein the intravenous injection of the sensitizer to the mammal delivers 10 to 50 mg ALA per kilo body weight in ALA hydrochloride equivalent or a molar equivalent of the derivative or the salt thereof;
(b) irradiating the mammalian bladder with an excitation light of 380-440 nm; and
(c) detecting fluorescence intensity at red light part of the bladder,
wherein steps (b) and (c) are performed between 2 hours and less than 5 hours after step (a).
6. The detection method according to claim 5 , wherein the 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is 5-aminolevulinic acid or a salt thereof.
7. The detection method according to claim 5 , wherein the bladder cancer is at a disease stage of pTis (intraepithelial cancer), pTa (without invasion), pT1 (with invasion to submucosal connective tissue), pT2 (with muscle invasion), or pT3 (with invasion to pericystic adipose tissue).
8. The detection method according to claim 7 , wherein the 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is 5-aminolevulinic acid or a salt thereof.
9. A method of using 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these for producing an orally administrable bladder cancer detecting sensitizer, wherein oral administration of the sensitizer to a mammal delivers 10 to 50 mg ALA per kilo body weight in ALA hydrochloride equivalent or a molar equivalent of the derivative or the salt thereof prior to detecting fluorescence intensity in the bladder, and wherein the time from the oral administration of the sensitizer to the detection is between 2 hours to less than 5 hours.
10. The method according to claim 9 , wherein the 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is 5-aminolevulinic acid or a salt thereof.
11. The detection method according to claim 9 , wherein the bladder cancer is at a disease stage of pTis (intraepithelial cancer), pTa (without invasion), pT1 (with invasion to submucosal connective tissue), pT2 (with muscle invasion), or pT3 (with invasion to pericystic adipose tissue).
12. The detection method according to claim 11 , wherein the 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is 5-aminolevulinic acid or a salt thereof.
13. A method of using 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these for producing an intravenously injectable bladder cancer detecting sensitizer, wherein intravenous injection of the sensitizer to a mammal delivers 10 to 50 mg ALA per kilo body weight in ALA hydrochloride equivalent or a molar equivalent of the derivative or the salt thereof prior to detecting fluorescence intensity in the bladder, and wherein the time from the intravenous injection of the sensitizer to the detection is between 2 hours to less than 5 hours.
14. The method according to claim 13 , wherein the 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is 5-aminolevulinic acid or a salt thereof.
15. The detection method according to claim 13 , wherein the bladder cancer is at a disease stage of pTis (intraepithelial cancer), pTa (without invasion), pT1 (with invasion to submucosal connective tissue), pT2 (with muscle invasion), or pT3 (with invasion to pericystic adipose tissue).
16. The detection method according to claim 15 , wherein the 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is 5-aminolevulinic acid or a salt thereof.